Thyroid eye disease

News

FDA clears Viridian's Tepezza rival for thyroid eye disease

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

News

Amgen scientists working in the lab, one woman and one man

Amgen scores with new thyroid eye disease formulation

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

Immunovant's thyroid eye disease drug flunks pivotal trials

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

News

Sling shoots at thyroid eye disease with its oral therapy

Amgen's thyroid eye disease blockbuster Tepezza, given by infusion, is facing competition from an oral alternative from Sling Therapeutics.

News

Viridian takes aim at Amgen's Tepezza with veligrotug data

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian

FDA clears Viridian's Tepezza rival for thyroid eye disease

Amgen scores with new thyroid eye disease formulation

Immunovant's thyroid eye disease drug flunks pivotal trials

Sling shoots at thyroid eye disease with its oral therapy

Viridian takes aim at Amgen's Tepezza with veligrotug data

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Thyroid eye disease

Editor's Picks